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Abstract
Nanocrystal budesonide (nanobudesonide) is a suspension for nebulization in patients with
steroid-responsive pulmonary disease such as asthma. The pharmacokinetics and safety of
the product were compared to those of Pulmicort® Respules™. Sixteen healthy volunteers
were administered nanobudesonide 0.5 and 1.0 mg, Pulmicort® Respules™ 0.5 mg and
placebo in a four-way, randomized crossover design. All nebulized formulations were
well-tolerated, with no evidence of bronchospasm. Nebulization times were significantly
shorter for nanobudesonide compared to Pulmicort® Respules™. Because of a low oral
bioavailability, plasma concentration of budesonide is a good marker of lung-delivered
dose. The pharmacokinetics of nanobudesonide 0.5 and 1.0 mg were approximately dose
proportional with respect to Cmax, AUC(0-t), and AUC(0-inf). Nanobudesonide 0.5 mg and
Pulmicort® Respules™ 0.5 mg exhibited similar AUC’s, suggesting a similar extent of
pulmonary absorption. A higher Cmax was noted with nanobudesonide 0.5 mg and the Tmax
was significantly different, suggesting a more rapid rate of drug delivery of
nanobudesonide 0.5 than Pulmicort® Respules™.

In conclusion, nebulized

nanobudesonide 0.5 mg was safe in healthy volunteers, with a similar extent of absorption
as Pulmicort Respules.
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Inhaled anti-inflammatory corticosteroid therapy is an important component of the
treatment regimen for chronic asthma. Practice guidelines recommend their use as firstline therapy for all cases of asthma, except mild intermittent asthma1,2. The use of inhaled
steroids early in the course of the disease is associated with improved outcomes compared
to treatment with beta 2 adrenergic agonists.3

Indeed, the early use of inhaled

corticosteroids may alter the natural history of the disease4, and possibly reduce the
irreversible airway obstruction associated with chronic inflammation of the lungs5.
Budesonide is a potent anti-inflammatory corticosteroid with low oral bioavailability. It
forms reversible intracellular fatty acid esters in airway and lung tissue, which may prolong
lung retention.6 Budesonide is available as a dry powder inhaler (DPI) and as PulmicortR
RespulesTM (AstraZeneca, Wilmington, DE), a suspension for inhalation with a jet-air
table-top nebulizer. Pulmicort® Respules™ is the only corticosteroid suspension for
inhalation available in the United States. The DPI form of inhalation therapy is often
limited by difficulty with coordination of inspiration, especially in pediatric patients. In
addition, the DPI’s require adequate inspiratory flow for drug delivery. For these reasons,
budesonide delivered by a table-top nebulizer has found increasing use as the best
alternative for delivery of corticosteroids to the lungs in children.
Nanobudesonide is a new formulation of budesonide that has been developed for use in a
table-top nebulizer. Suspended drug particles (the disperse phase) are in the 75-300
nanometer range in this formulation. This compares to particle size of 4,400 nanometer
for Pulmicort® RespulesTM.7 The small crystal size of budesonide in the nanocrystal
formulation gives the suspension solution-like characteristics, which may shorten delivery
time and improve intrapulmonary distribution compared to the existing preparation. In this
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study, the safety, delivery, and pharmacokinetics of nebulized nanobudesonide were
compared to Pulmicort® RespulesTM.

METHODS
Subjects
Sixteen healthy volunteers (13 males and 3 females) with a mean age of 32.5 (range 2540), mean height of 171.0  8.4 cm, and mean weight 76.8  14.5 kg participated in this
study. The study was approved by the Institutional Review Board of Thomas Jefferson
University in Philadelphia, PA. All subjects gave written informed consent to participate
prior to undergoing any study procedures. No study subject used a topical or systemic
corticosteroid, or ingested a cytochrome P4503A inhibitor within 4 weeks of study
initiation. Subjects with a history of bronchospasm or a screening FEV1/FVC of <80% of
predicted were excluded from participation.
Study Design
This was a randomized, double-blind, four-arm, single-dose cross-over study that
compared the pharmacokinetics and safety of nanobudesonide and Pulmicort® RespulesTM.
The four study arms were (1) placebo, (2) 0.5 mg of PulmicortR RespulesTM, (3) 0.5 mg of
nanobudesonide and (4) 1.0 mg of nanobudesonide. Healthy volunteers were admitted to
the Clinical Pharmacology Research Unit of Thomas Jefferson Hospital the day before
each treatment. Following an overnight fast, they received one of the four randomized
treatments. The study protocol specified that each subject was to receive treatments not
less than 5 or more than 10 days apart.

4

Spirometry, oximetry, clinical laboratory tests, ECG and vital signs were performed at
baseline and at specified intervals. The spirometer was calibrated on a daily basis. Adverse
events were monitored throughout the study. Twenty-four hours after each treatment,
subjects were reevaluated and discharged from the unit.
Test Drugs and Administration
Nanobudesonide and placebo were manufactured by Automated Liquid Packaging,
(Woodstock, IL) using plastic blow/fill/seal ampules.

Packaging and labeling were

performed by PCI Services - Clinical Services (Philadelphia, PA). The nanobudesonide
placebo consisted of the same ingredients as nanobudesonide without the budesonide.
Pulmicort® RespulesTM were purchased from a commercial source. Nebulizers were filled
by an unblinded investigational pharmacist. The fill volume for all treatments was 4.0 ml.
For the 0.5 mg nanobudesonide treatment arm, 2.0 ml of placebo was added to 2.0 ml of
active drug.
All treatments were administered by nebulization with a Pari LC Jet nebulizer and a Pari
LC Ultra compressor (PARI Respiratory Equipment, Inc., Monterey, CA).

A new

nebulizer was used for each treatment and each subject had all four treatments administered
with the same compressor. Compressors were checked with a calibration nebulizer each
day of use. Research personnel reviewed the inhalation procedure with each subject prior
to each treatment using a training nebulizer. Subjects were in a sitting position and trained
to inhale slowly and steadily through a mouthpiece with a target respiratory rate of 14 to
20 breaths per minute. Nose clips were utilized to avoid inspiration/expiration through the
nose. Nebulization was continued until one minute after sputtering was heard. The
duration of nebulization and the residual volumes were measured.
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Pharmacokinetics
Blood was drawn for budesonide levels pre-dose, at 5, 10, 15, 20, 25, 30, 40, and 60 min,
and 2, 3, 4, 6, 8, and 24 h post-dose. Time zero was the beginning of nebulization. Samples
were collected in tubes containing sodium heparin, immediately placed on ice, spun at 2200
g for 10 min.
Analysis of plasma samples was performed by Analytical BioChemistry Laboratories
(Columbia, MO) utilizing a validated HPLC-MS/MS method. Using nominal standard
concentrations of 60.1 pg/mL and 802 pg/mL, precision for this assay was 12.9% and
4.7% CV respectively, while accuracy was -8.6 to -2.8% RE of nominal standard
concentrations. Plasma was assayed for budesonide in 1.0 ml aliquots. Samples were
extracted on a 96-well C-18 SPE plates on a Tomtec Quadra 96 model 320. Desonide
(11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione) 30-1,000 pg/ml was used as an
internal standard. During validation, the correlation coefficient (r) was  0.9976.
Statistical Analyses
Statistical analyses were performed using SAS® Version 6.12 (SAS Institute, Cary, NC).
Safety variables of FEV1, adverse events and vital signs were analyzed with an analysis of
covariance at each time point. Clinical laboratory measurements and oximetry were
evaluated in each subject. The pharmacokinetic analyses were performed with SAS using
the sorting procedure, PROC GLM, PROC MEANS and G-PLOT. The slope of the
terminal phase was used to estimate AUC(0–inf). Analysis of variance (ANOVA) was
performed on untransformed and log transformed AUC and Cmax parameters. The model
included subject, period, and treatment. For the log transformed analysis adjusted means
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and confidence intervals were calculated for AUC(0-t), AUC (0-inf), Tmax and Cmax and backtransformed to the arithmetic scale. For untransformed data, treatments were compared for
the 95% confidence intervals for the difference between means. For transformed data, a
95% confidence interval was calculated for the ratio of two means. Subjects were
evaluated on an intent-to-treat basis, and those receiving at least one dose of the trial
medication were included in analyses.

RESULTS
Demographics
Sixteen subjects were enrolled and all completed the study. One subject exceeded the
maximum ten day window permitted between treatment arm 3 and 4 by four days. This
protocol variance did not jeopardize study integrity and this subject was included in the
analysis.
Pharmacokinetics
This study compared the pharmacokinetics of Pulmicort® and nanobudesonide delivered
by inhalation (Table 1). Because of the rapid absorption and the limited number of time
points during the first 10 min after the initiation of inhalation, Tmax values obtained are
considered estimates. Nevertheless, pairwise comparisons between Pulmicort® RespulesTM
and nanobudesonide 0.5 mg revealed significant Tmax (p=0.001) differences between
treatments. Indeed, maximum concentrations were achieved sooner in the nanobudesonide
0.5 mg treatment compared to Pulmicort®. In addition, pairwise comparisons of the log
transformed data revealed that the Cmax for nanobudesonide 0.5 mg was significantly
(p<0.001) higher than for a comparable dose of Pulmicort® RespulesTM. The extent of
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absorption of Pulmicort® RespulesTM 0.5 mg and nanobudesonide 0.5 mg, estimated by
AUC(0-t) and AUC(0-inf), was comparable, though formal bioequivalence testing was not
performed.

The pharmacokinetics of nanobudesonide 0.5 mg and 1.0 mg were

approximately dose proportional with respect to Cmax, AUC(0-t), and AUC(0-inf).
Nebulization Times and Residual Volumes
Nebulization was continued until 1 min after sputtering, which was not detected in one
subject receiving Pulmicort® RespulesTM and one receiving 0.5 mg of nanobudesonide
(Table 2). The nebulization times for these subjects were 15 and 16 min, respectively.
Nebulization times ranged from 4.0 to 16.0 min across all treatments and mean nebulization
times were 8.7 min for Pulmicort® RespulesTM, 7.1 min for nanobudesonide 0.5 mg, and
7.0 min for nanobudesonide1.0 mg. The mean nebulization time for the subjects receiving
Pulmicort® RespulesTM was significantly longer compared to that of the nanobudesonide
0.5 mg group (p=0.027) and the nanobudesonide 1.0 mg group (p=0.029). There were 5,
3 and 2 subjects with nebulization times greater than 10 min in the Pulmicort® RespulesTM,
nanobudesonide 0.5mg and nanobudesonide 1.0 mg groups, respectively.
Seven subjects had residual volumes greater than 1.0 ml; 4 in the Pulmicort ® RespulesTM
group, 2 in the nanobudesonide 0.5 mg group, 1 in the nanobudesonide 1.0 mg group, and
one in the placebo group. There was no clear relationship between higher residual volumes
and longer nebulization times. Three subjects had residual volumes greater than 1.0 ml in
more than one crossover treatment period.
Safety
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There were no significant adverse effects associated with the administration of the test
drugs. Four subjects reported a total of 8 adverse events after dosing with placebo. Two
subjects reported a total of 4 adverse events (nausea, dizziness, paresthesia, and rhinitis)
after dosing with Pulmicort® RespulesTM. One adverse event was reported with each of the
nanobudesonide groups. These included rhinitis (nanobudesonide 0.5 mg) and edema at a
venipuncture site (nanobudesonide 1.0 mg). All adverse effects were classified as mild.
There was no evidence of bronchospasm in any of the treatment arms. For FEV1, the
overall treatment effect was not significant at any evaluation (p0.111). In addition, there
were no clinically significant abnormalities in measured vital signs, pulse oximetry,
electrocardiograms, or clinical laboratory tests.

DISCUSSION
Inhaled steroids are the preferred anti-inflammatory therapy in the treatment of asthma.
Budesonide delivered by nebulization is effective in controlling pediatric asthma, as
measured using multiple clinical endpoints.8,9,10,11 The efficacy of inhaled budesonide is
predominantly mediated by local action, with systemic absorption contributing little, if
anything, to the control of inflammation in the lungs.12 Budesonide has an excellent safety
profile in children. Pediatric patients administered chronic inhaled steroids grow to a
normal adult height.13 However, safety concerns of a transient, decreased growth velocity
in children14 have resulted in under-utilization of inhaled corticosteroids in this age group.15
The goal of the new nanocrystal formulation budesonide is to maximize efficiency of
pulmonary delivery of drug, which may serve to obviate some of these safety concerns.
The delivery of budesonide by nebulization is a complex process that is affected by the
characteristics of the nebulizer and compressor, droplet size, properties of the formulation,
9

breathing pattern of the patient, and respiratory tree anatomy. A small component of the
orally deposited drug may be absorbed through the buccal mucosa. This was minimized
in the present study by the use of a mouthwash after nebulization. There is little or no
metabolism of budesonide in the lung.16 There is extensive hepatic first-pass metabolism
of swallowed budesonide, with an oral bioavailability of ~11%.17

Pharmacokinetic

evaluation of drug absorption from the lungs, therefore, provides an accurate and
reproducible method for comparing the dose delivered to the lung by different inhaler
systems or different formulations from the same inhaler system.18,19 A Medline search for
published reports of the pharmacokinetics of budesonide suspension delivered by a tabletop nebulizer yielded a single report from a study in 10 children. 20 However, neither the
budesonide particle size in the suspension nor the manufacturer of the suspension is
specified in this European study. Data on file with AstraZeneca reports that in children
with asthma, the Pari LC Jet Plus nebulizer with the Pari Master compressor delivered
approximately 25% of labeled budesonide to the patient.21 This delivered dose was
comparable to that in healthy adults.
In this study of healthy volunteers, the 0.5 mg nanobudesonide and the 0.5 mg Pulmicort®
Respules™ formulations produce a comparable budesonide AUC in plasma, indicating a
similar extent of absorption. Because the oral bioavailability of budesonide is relatively
low, it is likely that this observation reflects comparable pulmonary deposition for each
formulation.

The

nanobudesonide

formulation

exhibited

approximate

linear

pharmacokinetics between the 0.5 and 1.0 mg formulations. The nebulization times of
nanobudesonide 0.5 and 1.0 mg nanobudesonide were significantly shorter than those
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observed with Pulmicort® Respules™.

There were no significant adverse effects

associated with the delivery of the nanobudesonide formulation.
The comparable AUC, higher Cmax and lower Tmax of 0.5 mg nanobudesonide compared to
0.5 mg Pulmicort® Respules™ suggests more rapid drug delivery, or more rapid
absorption. If these differences are due to more rapid absorption, two mechanisms are
possible. Nanobudesonide could have more rapid dissolution of the in the airways, or a
more distal delivery of drug may facilitate rapid absorption. However, the PK data
presented do not allow discrimination between these possibilities. Drug distribution
studies will be required to determine the degree and kinetics of pulmonary deposition.
While some observations suggest that improved antiinflammatory drug distribution to
small airways might result in increased clinical efficacy,22 there is no clinical proof that
this is the case.23 Finally, results reported here in healthy adults should be extrapolated to
other populations with caution. Budesonide clearance20 and lung deposition19,24 differ in
pediatric and adult populations. Additionally, drug delivery to the lungs will differ in
asthmatic and healthy lungs.25 The subjects in this study were not balanced with regard to
gender and no subgroup analysis was performed owing to the small number (3) of females
participating.

However, no gender differences are present in the pharmacokinetic

parameters of Pulmicort® Respules™.21

The potential for differential regional lung

delivery of inhaled nanobudesonide based upon gender is unknown.26
In conclusion, nanobudesonide exhibited pharmacokinetics that were dose-proportional,
and nanobudesonide 0.5 mg yielded budesonide absorption that was comparable to
Pulmicort® Respules™. The higher Cmax and lower Tmax of 0.5 mg nanobudesonide
suggests a more rapid rate of either drug delivery or absorption compared to Pulmicort®
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Respules™. In addition, nanobudesonide administration demonstrated a safety profile that
was comparable to Pulmicort® Respules™. The significantly shorter nebulization time
with nanobudesonide compared to Pulmicort® Respules™ should be advantageous with
respect to patient compliance.
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Table 1
Pharmacokinetics of Pulmicort and Nanobudesonide
Pulmicort (0.5 mg)

Nanobudesonide (0.5 mg)

Nanobudesonide (1.0 mg)

PK Parameter

Mean (95% CI)

Mean (95% CI)

Mean (95% CI)

Tmax (min)

14.4 (11.4 – 18.0)

8.4 (5.4- 10.8)

11.4 (6.0- 16.2)

Cmax (pg/mL)

662 (416- 908)

1212 (751- 1674)

2484 1236- 3733)

AUC(0-t)
(pg∙hr/mL)

1518 (1071- 1966)

1472 (1171- 1773)

2725 (1981- 3469)

AUC(0-inf)
(pg∙hr/mL)

1631 (1125- 2137)

1658 (1284- 2031)

2893 (2118- 3668)

T1/2 (hr)

5.42

6.62

5.46
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Table 2
Mean Pulmicort and Nanobudesonide Nebulization Times
Duration (min)

SD

Range

Placebo

6.56

1.75

5-10

Pulmicort® Respules™ (0.5 mg)

8.70

3.38

5-16

Nanobudesonide (0.5 mg)

7.06

3.11

5-16

Nanobudesonide (1.0 mg)

6.95

2.48

4-13
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Figure. Time course of mean budesonide concentrations in plasma following oral administration of nanocrystal budesonide
0.5 mg (circles), nanocrystal budesonide 1.0 mg (squares), and Pulmicort® Respules™ 0.5 mg (+).
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